- Veranova is investing over $50 million to expand its Devens, Massachusetts site with bioconjugation development and cGMP manufacturing capabilities.
- The expansion supports antibody-drug conjugate (ADC) development and will add up to 70 new jobs by June 2026.
Veranova has announced a strategic investment to establish bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts facility. The investment, which exceeds $50 million, aims to enhance the company’s offering for the development and production of antibody-drug conjugates (ADCs) and other bioconjugates.
The new capabilities are expected to be operational by June 2026 and will include process and analytical development laboratories, grade C cleanroom space, and kilogram-scale manufacturing capacity for potent and non-potent bioconjugates. The initiative will also create up to 70 new jobs at the site.
Veranova’s Devens facility has over 15 years of experience in linker-payload development and manufacturing. It is FDA-approved and plays a central role in the company’s global network. The expansion supports the growing demand for U.S.-based CDMO and contract manufacturing services, particularly for critical drug substances.
“This investment will build on our core capabilities in complex chemistry, analytics and linker-payload synthesis,” said Mike Riley, CEO of Veranova, “and leverage our strategically located cGMP infrastructure to provide a differentiated solution to our customers.”
The Devens site is located near the Boston-Cambridge biotech hub and offers integrated services from early development through to commercial manufacturing.
